引用次数
引用: 25,091
H-指数: 68
I10-指数 : 220
出版物: 686
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): The phase II AVETUX-CRC trial (AIO KRK 0216).
Alexander Stein , Mascha Binder , Carsten Bokemeyer , Salah Eddin Al Batran
Journal of Clinical Oncology 35
2
2017
First-line Nab-paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer from Routine Clinical Practice
Uwe Pelzer , Arndt Vogel , Wolf Köster , Al-Batran Salah-Eddin
in Vivo 28 ( 6) 1135 -1140
8
2014
Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer
Lorenzen Sylvie , Spoerl Silvia , Al-Batran Salah-Eddin , Feith Markus
European Journal of Cancer 51 ( 14) 1918 -1926
11
2015
Impact of Age on the Feasibility and Efficacy of Neoadjuvant Chemotherapy in Patients with Locally Advanced Gastroesophageal Cancer: A Retrospective Pooled Analysis of Individual Patient Data
Lorenzen Sylvie , Spörl Silvia , Al-Batran Salah-Eddin , Novotny Alexander
Annals of Oncology 25 ii31 -ii31
2014
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial
G Huebner , , H Link , C H Kohne
British Journal of Cancer 100 ( 1) 44 -49
49
2009
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
A Atmaca , S-E Al-Batran , A Maurer , A Neumann
British Journal of Cancer 97 ( 2) 177 -182
210
2007
Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials
S-E Al-Batran , M Güntner , C Pauligk , M Scholz
British Journal of Cancer 103 ( 10) 1518 -1523
27
2010
The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial.
S-E Al-Batran , J Bischoff , G von Minckwitz , A Atmaca
British Journal of Cancer 94 ( 11) 1615 -1620
54
2006
Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer
S Lorenzen , C Pauligk , N Homann , H Schmalenberg
British Journal of Cancer 108 ( 3) 519 -526
60
2013
A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer
K Caca , N Prasnikar , F Kullmann , H Günther Derigs
British Journal of Cancer 108 ( 2) 265 -270
23
2013
Perioperative chemotherapy with gemcitabine plus cisplatin versus immediate radical liver resection alone in gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC-A phase III study based on" The German-Registry of Incidental Gallbladder Carcinoma"
TO Goetze , US Bankstahl , SA Lang , U Wittel
ONCOLOGY RESEARCH AND TREATMENT 43 ( SUPPL 4) 124 -124
2020
SPOTLIGHT: Phase 3 study of Zolbetuximab+ mFOLFOX6 versus placebo+ mFOLFOX6 in first-line claudin18. 2 (+)/HER2 (-) advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
F Lordick , K Shitara , S-E Al-Batran , Y-J Bang
Oncology Research and Treatment 44 218 -218
2021
Neoadjuvant chemotherapy with Gemcitabine plus Cisplatin followed by radical liver resection versus immediate radical liver resection alone in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC-a phase III study
TO Goetze , US Bankstahl , WO Bechstein , T Keck
ONCOLOGY RESEARCH AND TREATMENT 42 242 -242
2019
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
M Michl , S Stintzing , L Fischer von Weikersthal , T Decker
Annals of Oncology 27 ( 8) 1565 -1572
13
2016
S3-Leitlinie „Magenkarzinom”–
M Moehler , S-E Al-Batran , T Andus , Matthias Anthuber
Zeitschrift für Gastroenterologie 49 ( 04) 461 -531
125
2011
SAGA—a phase Ib/II single-arm, multicenter study of sacituzumab govitecan for patients with metastatic esophagogastric adenocarcinoma
B Kobitzsch , G Stocker , UT Hacker , S Junge
ESMO Gastrointestinal Oncology 4 100051 -100051
2024
Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinoma prior to gastrectomy
M Knoedler , J Koerfer , V Kunzmann , J Trojan
ONCOLOGY RESEARCH AND TREATMENT 40 158 -158
2017
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
S-E Al-Batran , Claudia Pauligk , RD Hofheinz , Sylvie Lorenzen
Journal of Clinical Oncology 37
5
2019
Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
E Goekkurt , S-E Al-Batran , U Mogck , C Pauligk
Annals of oncology 20 ( 3) 481 -485
18
2009
A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology
S-E Al-Batran , DW Mueller , M-R Rafiyan , D Kiselicki
ESMO open 8 ( 5) 101623 -101623
3
2023